Sales: $27.3 Billion Headcount: 17,000 Revenues: $27,281 (flat) Net Income: $4,566 (-26%) R&D: $4,977 (+8%) Despite flat sales in 2022, Gilead maintains its position at 13, with impressive growth in Oncology sales with growing demand for Trodelvy and Cell Therapies offset by a 30% drop in Veklury sales and expenses associated with the termination of the Trodelvy collaboration agreement with Everest, under which Gilead acquired remaining worldwide rights
References Arora JS, Kesler A, Min MS
Replenished levels of estrogen and progesterone also help you maintain muscle and bone mass, further preventing muscle atrophy that may come with weight loss
Microdosing may partially engage this pathway
Meta-analysis was performed using a random-effects model, with 13 eventually meeting the inclusion criteria